ENTPD5在上皮性卵巢癌组织中高表达:基于Oncomine数据库及生物信息学方法

目的 探讨ENTPD5在上皮性卵巢癌中的表达及临床价值。方法 通过Oncomine、TCGA数据库对ENTPD5在上皮性卵巢癌中的表达水平进行分析，UALCAN数据库分析ENTPD5表达水平与上皮性卵巢癌患者临床性状的相关性，基因富集分析（GSEA）软件分析ENTPD5在上皮性卵巢癌中的可能作用机制，CIBERSORT包探讨ENTPD5的表达量与免疫浸润的相关性。为进一步验证生物信息挖掘结果，RT-qPCR及Western blot检测23例上皮性卵巢癌组织和15例正常卵巢组织中ENTPD5的表达水平，免疫组化法检测50例上皮性卵巢癌石蜡样本和6例正常卵巢石蜡样本中ENTPD5的表达水平。结果 Oncomine、TCGA数据库发现与正常卵巢组织相比，ENTPD5在上皮性卵巢癌组织中表达显著增高（P<0.05），ENTPD5表达水平与上皮性卵巢癌患者生存呈负相关（P<0.05）。UALCAN数据库发现ENTPD5表达水平与患者年龄相关。GSEA软件分析发现ENTPD5参与ABC转运蛋白、WNT信号通路、胰岛素信号通路以及糖降解等过程，并在其中高度富集。CIBERSORT包分析显示 ENTPD5表达水平与NK细胞、肥大细胞及嗜酸性粒细胞的含量呈负相关（P<0.05）。RT-qPCR结果提示ENTPD5在上皮性卵巢癌组织中的表达水平（2.592±0.339）显著高于其在正常卵巢组织表达水平（1.00±0.123）（t=4.312，P<0.01）。Western blot结果提示上皮性卵巢癌组织中的ENTPD5表达显著高于正常卵巢组织（P<0.05）。免疫组化结果提示ENTPD5在上皮性卵巢癌组织中高表达。结论 ENTPD5在上皮性卵巢癌中高表达，其可能通过参与细胞多种功能过程以及细胞免疫浸润，参与上皮性卵巢 癌的发生发展。

ENTPD5 gene is highly expressed in epithelial ovarian cancer: analysis based on Oncomine database and bioinformatics

Objective To investigate the expression of ENTPD5 in epithelial ovarian cancer and explore its clinical implications. Methods The expression level of ENTPD5 in epithelial ovarian cancer was analyzed based on data from Oncomine and TCGA databases. The relationship between the expression level of ENTPD5 and clinical characteristics of the patients was analyzed using UALCAN database. Gene enrichment analysis (GSEA) was performed to explore the possible role of ENTPD5 in the occurrence and progression of epithelial ovarian cancer. CIBERSORT package was used to analyze the relationship between the expression of ENTPD5 and immune infiltration. The expression patterns of ENTPD5 were verified in 23 epithelial ovarian cancer tissues and 15 normal ovarian tissues using RT-qPCR and Western blotting; the expression of ENTPD5 protein was also detected immunohistochemically in 50 paraffin-embedded samples of epithelial ovarian cancer and 6 normal ovarian tissues. Results Analysis of Oncomine and TCGA databases showed that the expression of ENTPD5 was significantly higher in epithelial ovarian cancer tissues than in normal ovarian tissues (P<0.05), and its expression level was negatively correlated with the survival rate of the patients (P<0.05). Data from UALCAN database showed that the expression level of ENTPD5 was related with the age of patients. The results of GSEA suggested that ENTPD5 was involved in ABC transporter, WNT signaling pathway and insulin signaling, and the expression of ENTPD5 was negatively correlated with the contents of NK cells, mast cells and eosinophils (P<0.05). In clinical samples of epithelial ovarian cancer tissues, the expression of ENTPD5 was significantly higher than that in normal ovarian tissues at both the mRNA (P<0.01) and protein (P<0.05) levels. The paraffin-embedded samples also showed significantly higher expressions of ENTPD5 in epithelial ovarian cancer than in normal ovarian tissues (P<0.05). Conclusion ENTPD5 is highly expressed in epithelial ovarian cancer, which may promote the occurrence and progression of epithelial ovarian cancer by participating in multiple functional processes and cellular immune infiltration.